Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generic pharmaceuticals firm Actavis Group has received approval for irinotecan hydrochloride injection from the FDA for the treatment of patients with metastatic carcinoma of the colon or rectum.
Subscribe to our email newsletter
The company will begin distribution of the product immediately. Irinotecan hydrochloride injection, the generic equivalent to Pfizer’s Camptosar will be available in 40mg/2mL and 100mg/5mL sizes.
Doug Boothe, executive vice president of US commercial & administration, said: “The launch of irinotecan marks the expansion of company’s US portfolio into the injectable pharmaceuticals arena. Actavis has set its sights firmly on the hospital sector and currently has around 300 pending applications worldwide for injectable medicines. Furthermore, company’s ambitious pipeline comprises more than 60 new injectable projects, developed both internally and through established relationships with other developers.”